Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free SINT Stock Alerts

Sintx Technologies (SINT) Competitors

Sintx Technologies logo
$1.56 -0.16 (-9.30%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$1.49 -0.07 (-4.23%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SINT vs. PETV, MLSS, POAI, PSTV, and CTSO

Should you buy Sintx Technologies stock or one of its competitors? MarketBeat compares Sintx Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sintx Technologies include PetVivo (PETV), Milestone Scientific (MLSS), Predictive Oncology (POAI), Plus Therapeutics (PSTV), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Sintx Technologies compare to PetVivo?

PetVivo (NASDAQ:PETV) and Sintx Technologies (NASDAQ:SINT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Sintx Technologies has a consensus target price of $9.33, indicating a potential upside of 498.29%. Given Sintx Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sintx Technologies is more favorable than PetVivo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PetVivo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Sintx Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Sintx Technologies has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PetVivo$1.05M27.31-$10.95M-$0.38N/A
Sintx Technologies$1.02M6.61-$10.36M-$5.07N/A

In the previous week, PetVivo and PetVivo both had 1 articles in the media. Sintx Technologies' average media sentiment score of 1.87 beat PetVivo's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
PetVivo Neutral
Sintx Technologies Very Positive

24.5% of PetVivo shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PetVivo has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

PetVivo has a net margin of -902.82% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
PetVivo-902.82% -4,813.07% -281.78%
Sintx Technologies -1,058.60%-366.49%-115.04%

Summary

Sintx Technologies beats PetVivo on 8 of the 15 factors compared between the two stocks.

How does Sintx Technologies compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Sintx Technologies (NASDAQ:SINT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Milestone Scientific has a net margin of -52.01% compared to Sintx Technologies' net margin of -1,058.60%. Milestone Scientific's return on equity of -60.26% beat Sintx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
Sintx Technologies -1,058.60%-366.49%-115.04%

Milestone Scientific has higher revenue and earnings than Sintx Technologies. Milestone Scientific is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$8.90M3.92-$6.93M-$0.05N/A
Sintx Technologies$1.02M6.61-$10.36M-$5.07N/A

In the previous week, Milestone Scientific had 1 more articles in the media than Sintx Technologies. MarketBeat recorded 2 mentions for Milestone Scientific and 1 mentions for Sintx Technologies. Sintx Technologies' average media sentiment score of 1.87 beat Milestone Scientific's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Milestone Scientific Neutral
Sintx Technologies Very Positive

Milestone Scientific has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by company insiders. Comparatively, 4.1% of Sintx Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Milestone Scientific currently has a consensus price target of $1.00, suggesting a potential upside of 153.49%. Sintx Technologies has a consensus price target of $9.33, suggesting a potential upside of 498.29%. Given Sintx Technologies' higher probable upside, analysts clearly believe Sintx Technologies is more favorable than Milestone Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sintx Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Milestone Scientific beats Sintx Technologies on 10 of the 16 factors compared between the two stocks.

How does Sintx Technologies compare to Predictive Oncology?

Sintx Technologies (NASDAQ:SINT) and Predictive Oncology (NASDAQ:POAI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Sintx Technologies presently has a consensus price target of $9.33, suggesting a potential upside of 498.29%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Sintx Technologies is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sintx Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Sintx Technologies had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Sintx Technologies and 0 mentions for Predictive Oncology. Sintx Technologies' average media sentiment score of 1.87 beat Predictive Oncology's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Sintx Technologies Very Positive
Predictive Oncology Neutral

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sintx Technologies has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Sintx Technologies has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sintx Technologies$1.02M6.61-$10.36M-$5.07N/A
Predictive Oncology$1.66M15.01-$12.66M-$13.50N/A

Sintx Technologies has a net margin of -1,058.60% compared to Predictive Oncology's net margin of -5,065.23%. Sintx Technologies' return on equity of -366.49% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Sintx Technologies-1,058.60% -366.49% -115.04%
Predictive Oncology -5,065.23%-732.73%-235.55%

Summary

Sintx Technologies beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

How does Sintx Technologies compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Sintx Technologies (NASDAQ:SINT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 4.1% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Plus Therapeutics had 2 more articles in the media than Sintx Technologies. MarketBeat recorded 3 mentions for Plus Therapeutics and 1 mentions for Sintx Technologies. Sintx Technologies' average media sentiment score of 1.87 beat Plus Therapeutics' score of 0.62 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Plus Therapeutics Positive
Sintx Technologies Very Positive

Plus Therapeutics currently has a consensus target price of $56.40, suggesting a potential upside of 1,252.52%. Sintx Technologies has a consensus target price of $9.33, suggesting a potential upside of 498.29%. Given Plus Therapeutics' higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than Sintx Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Plus Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Sintx Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Sintx Technologies has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus Therapeutics$5.21M5.51-$22.39M-$2.30N/A
Sintx Technologies$1.02M6.61-$10.36M-$5.07N/A

Plus Therapeutics has a net margin of -230.24% compared to Sintx Technologies' net margin of -1,058.60%. Plus Therapeutics' return on equity of -198.48% beat Sintx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Plus Therapeutics-230.24% -198.48% -73.13%
Sintx Technologies -1,058.60%-366.49%-115.04%

Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Summary

Plus Therapeutics beats Sintx Technologies on 9 of the 16 factors compared between the two stocks.

How does Sintx Technologies compare to Cytosorbents?

Sintx Technologies (NASDAQ:SINT) and Cytosorbents (NASDAQ:CTSO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Comparatively, 7.8% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sintx Technologies currently has a consensus target price of $9.33, indicating a potential upside of 498.29%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,314.47%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than Sintx Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sintx Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cytosorbents
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cytosorbents has a net margin of -31.85% compared to Sintx Technologies' net margin of -1,058.60%. Cytosorbents' return on equity of -235.57% beat Sintx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Sintx Technologies-1,058.60% -366.49% -115.04%
Cytosorbents -31.85%-235.57%-37.88%

Cytosorbents has higher revenue and earnings than Sintx Technologies. Cytosorbents is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sintx Technologies$1.02M6.61-$10.36M-$5.07N/A
Cytosorbents$37.20M0.64-$8.20M-$0.19N/A

In the previous week, Cytosorbents had 1 more articles in the media than Sintx Technologies. MarketBeat recorded 2 mentions for Cytosorbents and 1 mentions for Sintx Technologies. Sintx Technologies' average media sentiment score of 1.87 beat Cytosorbents' score of 1.32 indicating that Sintx Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Sintx Technologies Very Positive
Cytosorbents Positive

Sintx Technologies has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Summary

Cytosorbents beats Sintx Technologies on 11 of the 16 factors compared between the two stocks.

Get Sintx Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SINT vs. The Competition

Export
MetricSintx TechnologiesMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market CapN/A$7.63B$7.05B$12.61B
Dividend YieldN/A1.32%2.68%8.00%
P/E Ratio-0.3150.2827.1124.26
Price / Sales6.6176.45589.96117.88
Price / CashN/A26.8529.2249.36
Price / Book1.957.3210.746.29
Net Income-$10.36M$162.30M$3.58B$330.66M
7 Day Performance-15.68%-0.99%-2.11%-1.35%
1 Month Performance-26.42%0.19%3.27%-0.64%
1 Year Performance-47.47%4.08%26.31%19.08%

Sintx Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SINT
Sintx Technologies
3.1587 of 5 stars		$1.56
-9.3%		$9.33
+498.3%		-53.2%$0.00$1.02MN/A40
PETV
PetVivo
N/A$0.82
+2.4%		N/A-3.8%$30.79M$1.05MN/A20
MLSS
Milestone Scientific
1.1286 of 5 stars		$0.34
-3.6%		$1.00
+196.5%		-40.8%$29.83M$8.90MN/A30
POAI
Predictive Oncology
N/A$8.41
+18.8%		N/A-37.9%$28.54M$1.66MN/A30
PSTV
Plus Therapeutics
2.5323 of 5 stars		$3.92
-3.2%		$56.40
+1,338.8%		-53.6%$27.88M$5.21MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SINT) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your money is changing
Porter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...
Porter & Company | Sponsoredtc pixel
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Trump Set to Unleash 219-Year-Old “Super Weapon” on U.S. Soil
Four-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...
Paradigm Press | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel